SRP273813 Track Settings
 
Whole genome methylation sequencing of circulating tumor cells (CTCs) in Lung cancer. [Adjacent Normal Tissue, Blood, Lung]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
SRX8834184 
SRX8834186 
SRX8834187 
SRX8834188 
SRX8834189 
SRX8834190 
SRX8834191 
SRX8834192 
SRX8834193 
SRX8834194 
SRX8834195 
SRX8834196 
SRX8834199 
SRX8834200 
SRX8834201 
SRX8834202 
SRX8834203 
SRX9588320 
SRX9588323 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX8834184  CpG methylation  Blood / SRX8834184 (CpG methylation)   schema 
hide
 SRX8834184  HMR  Blood / SRX8834184 (HMR)   schema 
hide
 SRX8834186  CpG methylation  Adjacent Normal Tissue / SRX8834186 (CpG methylation)   schema 
hide
 SRX8834199  HMR  Blood / SRX8834199 (HMR)   schema 
hide
 SRX8834187  CpG methylation  Adjacent Normal Tissue / SRX8834187 (CpG methylation)   schema 
hide
 SRX8834200  HMR  Blood / SRX8834200 (HMR)   schema 
hide
 SRX8834188  CpG methylation  Adjacent Normal Tissue / SRX8834188 (CpG methylation)   schema 
hide
 SRX8834201  HMR  Blood / SRX8834201 (HMR)   schema 
hide
 SRX8834189  CpG methylation  Adjacent Normal Tissue / SRX8834189 (CpG methylation)   schema 
hide
 SRX8834202  HMR  Blood / SRX8834202 (HMR)   schema 
hide
 SRX8834190  CpG methylation  Adjacent Normal Tissue / SRX8834190 (CpG methylation)   schema 
hide
 SRX8834203  HMR  Blood / SRX8834203 (HMR)   schema 
hide
 SRX8834191  CpG methylation  Lung / SRX8834191 (CpG methylation)   schema 
hide
 SRX8834192  CpG methylation  Lung / SRX8834192 (CpG methylation)   schema 
hide
 SRX8834193  CpG methylation  Lung / SRX8834193 (CpG methylation)   schema 
hide
 SRX8834194  CpG methylation  Lung / SRX8834194 (CpG methylation)   schema 
hide
 SRX8834195  CpG methylation  Lung / SRX8834195 (CpG methylation)   schema 
hide
 SRX8834196  CpG methylation  Blood / SRX8834196 (CpG methylation)   schema 
hide
 SRX8834199  CpG methylation  Blood / SRX8834199 (CpG methylation)   schema 
hide
 SRX8834200  CpG methylation  Blood / SRX8834200 (CpG methylation)   schema 
hide
 SRX8834201  CpG methylation  Blood / SRX8834201 (CpG methylation)   schema 
hide
 SRX8834202  CpG methylation  Blood / SRX8834202 (CpG methylation)   schema 
hide
 SRX8834203  CpG methylation  Blood / SRX8834203 (CpG methylation)   schema 
hide
 SRX9588320  CpG methylation  Blood / SRX9588320 (CpG methylation)   schema 
hide
 SRX9588323  CpG methylation  Blood / SRX9588323 (CpG methylation)   schema 
    

Study title: Whole genome methylation sequencing of circulating tumor cells (CTCs) in Lung cancer.
SRA: SRP273813
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX8834184 Blood 0.684 4.3 35543 1101.4 539 898.7 147 58356.1 0.986 CTC1
SRX8834186 Adjacent Normal Tissue 0.759 3.7 18934 1290.2 176 151928.8 253 123774.6 0.997 N1
SRX8834187 Adjacent Normal Tissue 0.735 3.6 15908 1069.9 199 138676.8 193 75656.6 0.997 N3
SRX8834188 Adjacent Normal Tissue 0.776 3.6 17468 1100.4 173 107125.7 196 100321.8 0.997 N4
SRX8834189 Adjacent Normal Tissue 0.748 4.6 22664 1402.0 396 68825.5 462 48114.2 0.997 N5
SRX8834190 Adjacent Normal Tissue 0.766 3.6 17168 1168.0 158 174452.4 231 112844.5 0.997 N6
SRX8834191 Lung 0.748 3.6 16816 1166.0 221 121261.0 357 195649.0 0.997 T1
SRX8834192 Lung 0.505 3.6 16370 6979.9 519 55092.2 861 954081.1 0.997 T3
SRX8834193 Lung 0.762 3.7 16602 1229.9 207 133656.9 319 131509.0 0.996 T4
SRX8834194 Lung 0.590 4.5 15945 9771.8 684 42311.4 932 1249917.1 0.997 T5
SRX8834195 Lung 0.705 3.7 16906 1371.7 290 96265.3 112 208116.1 0.997 T6
SRX8834196 Blood 0.695 4.2 13479 865.7 28 1273.1 15 942173.1 0.987 CTC3
SRX8834199 Blood 0.715 2.9 29648 1163.0 335 929.7 78 91945.9 0.987 CTC6
SRX8834200 Blood 0.545 6.1 34193 2673.5 695 1048.0 719 1245948.5 0.983 CTC7
SRX8834201 Blood 0.558 6.0 30472 2373.3 224 900.4 567 1569518.2 0.989 CTC8
SRX8834202 Blood 0.603 2.4 48236 2769.8 157 931.8 717 853644.7 0.989 CTC9
SRX8834203 Blood 0.597 7.3 44540 2934.4 663 971.2 1022 782859.8 0.986 CTC10
SRX9588320 Blood 0.611 4.0 2793 691.9 21 1367.8 2 802500.0 0.959 CTC11
SRX9588323 Blood 0.684 4.2 7720 641.3 22 1215.6 14 1578469.3 0.987 CTC14

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.